
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Key elements for discussion with patients around their fibromyalgia diagnosis are highlighted by a medical expert.
Video content above is prompted by the following: